Although growth stock picks can be highly volatile, they can make good long-term investments. They may be well-known stars or quiet gems, but they do share one common attribute—they are growing at a higher-than-average rate within their industry, or within the market as a whole, and could keep growing for years or decades.
And keep in mind that we focus on growth stocks, which have a good long-term history and favourable prospects. We downplay momentum stocks that tend to attract many investors simply because they are moving faster than the market averages, but are liable to fall sharply when their momentum fades.
There’s room for growth stock investing in your portfolio, but make sure you follow our TSI Network three-part Successful Investor strategy for your overall portfolio:
- Invest mainly in well-established companies;
- Spread your money out across most if not all of the five main economic sectors (Manufacturing & Industry; Resources & Commodities; Consumer; Finance; Utilities);
- Downplay or avoid stocks in the broker/media limelight.
Make better stock picks when you read this FREE Special Report, Canadian Growth Stocks: WestJet Stock, RioCan Stock and More.
The efficiency improvements are freeing up cash for dividends: Stanley recently raised its payout by 5.8%. The new annual rate of $2.20 yields 2.0%.
Stanley is a buy.
...
To win regulatory approval, the company agreed to expand its high-speed fibre-optic Internet service to more areas and upgrade Internet connections to schools and public libraries.
By combining broadcasting and other facilities, AT&T should save $2.5 billion annually by the end of the third year. Adding DirecTV will also help the company negotiate better content deals with sports leagues and TV networks.
...
Alliant gets just under half of its power from coalburning plants, so it’s in a better position than Ameren (see left) to comply with new air-quality standards. Even so, it plans to spend $10.0 billion on upgrades over the next eight years. This includes converting coal plants to gas and replacing transmission lines.
Warmer weather has also hurt Alliant’s gas and electricity sales. In the first quarter of 2015, revenue fell 5.8%, to $897.4 million from $952.8 million a year earlier. Earnings declined 10.6%, to $96.6 million, or $0.87 a share, from $108.0 million, or $0.97.
...
In the three months ended March 31, 2015, warmer-than-usual winter weather prompted Ameren’s customers to use less power and gas for heating. That cut its revenue by 2.4%, to $1.56 billion from $1.59 billion a year earlier.
However, the company recently refinanced some debt at lower rates. That reduced its interest charges, boosting earnings by 11.3%, to $108 million, or $0.45 a share, from $97 million, or $0.40.
...
The new firm is North America’s third-largest food and beverage company and the world’s fifth biggest. It will have $29.1 billion of annual revenue, including eight brands with over $1 billion in yearly sales.
The stock trades at a high 27.5 times the $2.84 a share the new firm should earn in 2015. However, that multiple should improve in the next few years as the company starts to see savings from merging plants and combining distribution networks. The $2.20 dividend yields 2.8%.
...
Per-share profits gained 10.2%, to $2.27 from $2.06. Sales gained 4.0%, to $859.8 million from $827.1 million. Bard gets two-thirds of its sales from customers outside of the U.S. If you exclude the negative impact of currency-exchange rates, its sales rose 8%.
The stock trades at 21.6 times the $9.02 a share Bard will probably earn in 2015. That’s a reasonable multiple for the company, which spends 7% of its revenue on research.
...
The company has sold most of its chipmaking operations over the past few years, so if this technology becomes commercially viable, IBM will license it to other manufacturers. Faster chips would also make the company’s analytics software perform better.
IBM is a buy.
...
Before former parent Baxter spun off Baxalta, it bought Germany-based SuppreMol for $225 million. This firm develops drugs for disorders in which the immune system attacks healthy tissue.
Baxter also paid $900 million for the Oncaspar leukemia drug, from Italian pharmaceutical firm Sigma- Tau Finanziaria. Oncaspar has $100 million in annual sales.
...
On July 1, 2015, the company spun off Baxalta, a maker of vaccines and other drugs. Investors received one Baxalta share as a tax-deferred dividend for every Baxter share they held.
Baxter still owns 19.5% of Baxalta; it plans to sell or distribute these shares within five years. As a separate firm, Baxter expects its research costs to fall from 6% of revenue to less than 5.5%.
...
As a separate firm, Gannett should earn $1.98 a share in 2015, and the stock trades at just 6.6 times that figure. The $0.64 dividend yields 4.9%.
Gannett is still a buy.
...